Valuation: Abbott Laboratories (Pakistan) Limited

Capitalization 87.35B 313M 266M 244M 230M 428M 29.87B 432M 2.89B 1.13B 14.22B 1.18B 1.15B 49.22B P/E ratio 2024
23.2x
P/E ratio 2025 -
Enterprise value 87.35B 313M 266M 244M 230M 428M 29.87B 432M 2.89B 1.13B 14.22B 1.18B 1.15B 49.22B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
16.36%
Yield 2024 *
-
Yield 2025 3.81%
1 day+0.07%
1 week-0.61%
Current month+1.11%
1 month-7.28%
3 months-25.29%
6 months-16.92%
Current year-15.03%
1 week 888
Extreme 888
922.98
1 month 866
Extreme 866
1,017
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 31/03/2016
Director of Finance/CFO - 31/10/2019
Chief Tech/Sci/R&D Officer - 31/05/2011
Director TitleAgeSince
Director/Board Member - 28/02/2009
Director/Board Member - 03/06/2014
Chairman - 29/05/2022
Change 5d. change 1-year change 3-years change Capi.($)
+0.07%-0.61%+6.01%+123.64% 313M
+1.95%-0.10%+31.64%+122.02% 846B
+0.05%-1.24%+43.58%+37.54% 533B
+0.61%-2.58%+9.85%+38.33% 356B
-0.94%-0.38%+22.40%+11.63% 324B
+1.18%-0.07%+31.86%+13.23% 282B
+0.30%-0.12%+25.07%+22.81% 278B
-0.09%-1.62%+46.48%-5.33% 275B
+3.34%+6.03%-32.48%-48.08% 203B
-0.64%+1.77%+23.97%+41.89% 179B
Average +0.58%-0.38%+20.84%+35.77% 327.57B
Weighted average by Cap. +0.78%-0.72%+26.62%+44.88%

Financials

2024 2025
Net sales 68.18B 245M 208M 190M 179M 334M 23.31B 337M 2.25B 880M 11.1B 918M 899M 38.42B 75.4B 271M 230M 210M 198M 370M 25.78B 373M 2.49B 973M 12.28B 1.02B 994M 42.49B
Net income 5.23B 18.78M 15.94M 14.6M 13.76M 25.67M 1.79B 25.88M 173M 67.57M 852M 70.48M 69M 2.95B 7.97B 28.59M 24.26M 22.22M 20.95M 39.07M 2.72B 39.39M 263M 103M 1.3B 107M 105M 4.49B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
11/05/26 892.28 +0.07% 11,197
08/05/26 891.67 -2.87% 35,678
07/05/26 918.02 +0.98% 10,097
06/05/26 909.07 +1.35% 14,567
05/05/26 896.93 -0.10% 9,622
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
892.28PKR
Average target price
1,300.00PKR
Spread / Average Target
+45.69%

Annual profits - Rate of surprise